Berry Genomics Co Ltd

SHE:000710 China Diagnostics & Research
Market Cap
$536.26 Million
CN¥3.93 Billion CNY
Market Cap Rank
#11685 Global
#2793 in China
Share Price
CN¥11.13
Change (1 day)
-2.02%
52-Week Range
CN¥11.05 - CN¥16.61
All Time High
CN¥90.95
Categories
Companies in China Diagnostics & Research
About

Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more

Berry Genomics Co Ltd (000710) - Net Assets

Latest net assets as of September 2025: CN¥1.65 Billion CNY

Based on the latest financial reports, Berry Genomics Co Ltd (000710) has net assets worth CN¥1.65 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.34 Billion) and total liabilities (CN¥694.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥1.65 Billion
% of Total Assets 70.37%
Annual Growth Rate 13.44%
5-Year Change -29.2%
10-Year Change 1357.37%
Growth Volatility 228.56

Berry Genomics Co Ltd - Net Assets Trend (1994–2024)

This chart illustrates how Berry Genomics Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Berry Genomics Co Ltd (1994–2024)

The table below shows the annual net assets of Berry Genomics Co Ltd from 1994 to 2024.

Year Net Assets Change
2024-12-31 CN¥1.72 Billion -9.47%
2023-12-31 CN¥1.89 Billion -18.66%
2022-12-31 CN¥2.33 Billion -7.70%
2021-12-31 CN¥2.52 Billion +4.18%
2020-12-31 CN¥2.42 Billion +3.21%
2019-12-31 CN¥2.35 Billion +20.84%
2018-12-31 CN¥1.94 Billion +24.47%
2017-12-31 CN¥1.56 Billion +1267.92%
2016-12-31 CN¥114.08 Million -3.07%
2015-12-31 CN¥117.69 Million -9.49%
2014-12-31 CN¥130.03 Million +7.46%
2013-12-31 CN¥121.00 Million -2.17%
2012-12-31 CN¥123.68 Million +0.96%
2011-12-31 CN¥122.50 Million +0.23%
2010-12-31 CN¥122.22 Million +6.74%
2009-12-31 CN¥114.51 Million +9.74%
2008-12-31 CN¥104.34 Million +10.41%
2007-12-31 CN¥94.51 Million -5.29%
2006-12-31 CN¥99.78 Million +1.21%
2005-12-31 CN¥98.59 Million -12.56%
2004-12-31 CN¥112.75 Million +0.57%
2003-12-31 CN¥112.11 Million +2.97%
2002-12-31 CN¥108.87 Million -32.58%
2001-12-31 CN¥161.48 Million -22.01%
2000-12-31 CN¥207.06 Million -6.27%
1999-12-31 CN¥220.90 Million +4.48%
1998-12-31 CN¥211.44 Million +13.93%
1997-12-31 CN¥185.58 Million +150.97%
1996-12-31 CN¥73.95 Million +79.71%
1995-12-31 CN¥41.15 Million +5.42%
1994-12-31 CN¥39.03 Million --

Equity Component Analysis

This analysis shows how different components contribute to Berry Genomics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 6454237700.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥64.54 Million 3.84%
Common Stock CN¥353.52 Million 21.05%
Other Comprehensive Income CN¥439.84 Million 26.19%
Other Components CN¥821.57 Million 48.92%
Total Equity CN¥1.68 Billion 100.00%

Berry Genomics Co Ltd Competitors by Market Cap

The table below lists competitors of Berry Genomics Co Ltd ranked by their market capitalization.

Company Market Cap
Custom Truck One Source Inc
NYSE:CTOS
 		$377.88 Million
Beijing Comens New Materials
SHE:300200
 		$377.89 Million
Xinjiang Lixin Energy Co. Ltd. A
SHE:001258
 		$377.98 Million
Chengdu JOUAV Automation Tech Co. Ltd. A
SHG:688070
 		$377.98 Million
Suntront Tech
SHE:300259
 		$377.86 Million
ABIVAX Société Anonyme
PINK:AAVXF
 		$377.86 Million
Myson Century, Inc.
TWO:5314
 		$377.75 Million
SEALSQ Corp
NASDAQ:LAES
 		$377.72 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Berry Genomics Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,864,035,046 to 1,679,476,362, a change of -184,558,684 (-9.9%).
  • Net loss of 192,428,499 reduced equity.
  • Dividend payments of 8,692,207 reduced retained earnings.
  • Other comprehensive income increased equity by 423,341,786.
  • Other factors decreased equity by 406,779,764.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥-192.43 Million -11.46%
Dividends Paid CN¥8.69 Million -0.52%
Other Comprehensive Income CN¥423.34 Million +25.21%
Other Changes CN¥-406.78 Million -24.22%
Total Change CN¥- -9.90%

Book Value vs Market Value Analysis

This analysis compares Berry Genomics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.34x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 43.00x to 2.34x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1994-12-31 CN¥0.26 CN¥11.13 x
1995-12-31 CN¥0.27 CN¥11.13 x
1996-12-31 CN¥0.46 CN¥11.13 x
1997-12-31 CN¥1.21 CN¥11.13 x
1998-12-31 CN¥1.38 CN¥11.13 x
1999-12-31 CN¥1.44 CN¥11.13 x
2000-12-31 CN¥1.35 CN¥11.13 x
2001-12-31 CN¥1.06 CN¥11.13 x
2002-12-31 CN¥0.72 CN¥11.13 x
2003-12-31 CN¥0.74 CN¥11.13 x
2004-12-31 CN¥0.75 CN¥11.13 x
2005-12-31 CN¥0.65 CN¥11.13 x
2006-12-31 CN¥0.66 CN¥11.13 x
2007-12-31 CN¥0.62 CN¥11.13 x
2008-12-31 CN¥0.64 CN¥11.13 x
2009-12-31 CN¥0.71 CN¥11.13 x
2010-12-31 CN¥0.77 CN¥11.13 x
2011-12-31 CN¥0.77 CN¥11.13 x
2012-12-31 CN¥0.78 CN¥11.13 x
2013-12-31 CN¥0.76 CN¥11.13 x
2014-12-31 CN¥0.86 CN¥11.13 x
2015-12-31 CN¥0.78 CN¥11.13 x
2016-12-31 CN¥0.57 CN¥11.13 x
2017-12-31 CN¥6.07 CN¥11.13 x
2018-12-31 CN¥5.40 CN¥11.13 x
2019-12-31 CN¥6.57 CN¥11.13 x
2020-12-31 CN¥6.81 CN¥11.13 x
2021-12-31 CN¥7.04 CN¥11.13 x
2022-12-31 CN¥6.51 CN¥11.13 x
2023-12-31 CN¥5.28 CN¥11.13 x
2024-12-31 CN¥4.75 CN¥11.13 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Berry Genomics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -11.46%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -17.85%
  • • Asset Turnover: 0.45x
  • • Equity Multiplier: 1.42x
  • Recent ROE (-11.46%) is below the historical average (1.14%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1994 31.52% 16.15% 0.76x 2.57x CN¥8.40 Million
1995 36.01% 13.84% 0.78x 3.32x CN¥10.70 Million
1996 22.62% 13.98% 0.57x 2.86x CN¥8.80 Million
1997 13.84% 22.28% 0.39x 1.59x CN¥6.99 Million
1998 11.37% 19.95% 0.38x 1.48x CN¥2.84 Million
1999 6.33% 13.78% 0.33x 1.37x CN¥-7.98 Million
2000 0.79% 2.03% 0.24x 1.63x CN¥-18.74 Million
2001 -27.84% -86.72% 0.14x 2.24x CN¥-60.27 Million
2002 -46.67% -81.14% 0.26x 2.22x CN¥-61.70 Million
2003 2.83% 3.90% 0.31x 2.30x CN¥-8.04 Million
2004 0.57% 0.53% 0.43x 2.47x CN¥-10.64 Million
2005 -14.48% -10.93% 0.56x 2.37x CN¥-24.14 Million
2006 1.20% 0.80% 0.61x 2.45x CN¥-8.79 Million
2007 -13.43% -7.03% 0.80x 2.39x CN¥-22.14 Million
2008 2.89% 0.98% 0.92x 3.19x CN¥-6.93 Million
2009 9.68% 2.56% 1.12x 3.39x CN¥-344.99K
2010 6.95% 1.74% 1.21x 3.30x CN¥-3.54 Million
2011 0.43% 0.12% 1.15x 3.04x CN¥-11.17 Million
2012 0.33% 0.12% 0.97x 2.89x CN¥-11.41 Million
2013 -5.33% -2.35% 0.64x 3.55x CN¥-17.70 Million
2014 5.29% 2.51% 0.61x 3.43x CN¥-6.12 Million
2015 -11.05% -5.65% 0.46x 4.24x CN¥-24.78 Million
2016 -3.67% -1.69% 0.45x 4.80x CN¥-15.59 Million
2017 15.15% 19.87% 0.65x 1.18x CN¥79.09 Million
2018 14.08% 18.62% 0.66x 1.14x CN¥77.75 Million
2019 16.78% 24.15% 0.53x 1.32x CN¥157.78 Million
2020 8.82% 13.68% 0.47x 1.36x CN¥-28.18 Million
2021 -4.41% -7.72% 0.40x 1.41x CN¥-358.88 Million
2022 -10.96% -18.44% 0.43x 1.39x CN¥-482.39 Million
2023 -22.92% -37.10% 0.42x 1.47x CN¥-613.60 Million
2024 -11.46% -17.85% 0.45x 1.42x CN¥-360.38 Million

Industry Comparison

This section compares Berry Genomics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $3,062,444,466
  • Average return on equity (ROE) among peers: 12.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Berry Genomics Co Ltd (000710) CN¥1.65 Billion 31.52% 0.42x $377.87 Million
Zhejiang DiAn Diagnostics Co (300244) $9.50 Billion 15.09% 1.22x $1.14 Billion
Beijing Strong Biotechnologies Inc (300406) $1.70 Billion 17.66% 0.10x $317.93 Million
Ningbo MedicalSystem Biotechnology Co Ltd (300439) $308.32 Million 33.58% 0.53x $283.14 Million
Maccura Biotechnology Co Ltd (300463) $4.54 Billion 21.06% 0.45x $576.46 Million
Guangdong Hybribio Biotech Co Ltd (300639) $4.05 Billion -16.18% 0.14x $319.65 Million
BGI Genomics Co Ltd (300676) $4.25 Billion 9.09% 0.23x $1.45 Billion
Amoy Diagnostics Co Ltd (300685) $307.91 Million 21.77% 0.15x $834.75 Million
Shanghai Labway Clinical Laboratory Co Ltd (301060) $1.82 Billion -6.01% 0.44x $226.85 Million
SMO ClinPlus Co. Ltd. (301257) $1.08 Billion 12.47% 0.26x $347.98 Million